Gilead Tops Q1 Estimates with 12% HIV, 28% Trodelvy Sales Growth
GILD•Gilead reported Q1 adjusted EPS of $1.52, beating estimates of $1.46, and delivered revenue of $6.7 billion versus $6.65 billion expected, driven by a 12% increase in HIV drug sales and a 28% gain in Trodelvy sales. The company lowered its 2026 EPS guidance to $5.85–$5.95 from $6.10–$6.20, triggering a share pullback.
1. Q1 Financial Results
Gilead delivered adjusted EPS of $1.52 in the first quarter, surpassing the consensus forecast of $1.46, and reported revenue of $6.7 billion compared with expectations of $6.65 billion, underscoring strong operational execution.
2. HIV and Trodelvy Performance
The HIV franchise saw sales climb 12% year-over-year to approximately $3.1 billion, while cancer therapy Trodelvy recorded a 28% sales increase to roughly $550 million, together accounting for the bulk of top-line growth.
3. Guidance Revision
Management revised its full-year 2026 adjusted EPS outlook downward to a range of $5.85–$5.95 from a prior range of $6.10–$6.20, citing anticipated pricing pressures and increased investment in clinical development.
4. Market Reaction
Shares of Gilead fell by around 3% in after-hours trading as investors weighed the robust quarterly beat against the more conservative earnings outlook for the remainder of the year.
